Angelman Syndrome

  1. Overview and History
  2. Genomic Imprinting and the UBE3A Gene
  3. Molecular Mechanisms: Deletion, UPD, Imprinting Defect, UBE3A Mutation
  4. Clinical Features: Severe Intellectual Disability and Absent Speech
  5. Happy Demeanor and Movement Disorder
  6. Seizures and EEG Characteristics
  7. Diagnosis
  8. Treatment: Seizure Management and Communication
  9. Emerging Therapies: UBE3A Unsilencing
  10. Key Research Papers
  11. Featured Videos
  12. Connections

Overview and History

Angelman syndrome (AS) is a rare neurogenetic disorder that affects approximately 1 in 12,000 to 20,000 people. It is caused by the loss of function of a single gene — the maternal copy of UBE3A — in the brain's neurons. The result is a recognizable cluster of features: severe intellectual disability, the near-complete absence of spoken language, a characteristic happy and sociable demeanor with frequent smiling and laughter, and a movement disorder marked by an unsteady, wide-based gait. Despite the severity of cognitive impairment, individuals with Angelman syndrome are typically highly engaged with the world around them and capable of forming meaningful relationships.

The condition was first described in 1965 by British pediatrician Harry Angelman, who published a case report of three children he had observed — each with jerky, puppet-like movements, a happy facial expression with frequent laughter, and a severe lack of speech. He titled his paper "Puppet Children," and for decades the disorder was informally called "happy puppet syndrome." That label is now considered offensive and has been entirely abandoned by the medical community. The name "Angelman syndrome" was formally adopted in the 1980s as the appropriate medical term. For many years after Angelman's report, the condition was under-recognized and often misdiagnosed as cerebral palsy or autism; it was not until the chromosomal basis was identified in the late 1980s that a reliable genetic diagnosis became possible.

Today Angelman syndrome is understood in remarkable molecular detail. It stands as one of the clearest examples in human medicine of a phenomenon called genomic imprinting — the biology of genes that are turned on or off depending on which parent contributed them. This understanding has opened the door to potential treatments that were inconceivable even a decade ago, including approaches that aim to awaken the silent but intact copy of UBE3A that every person with AS carries in their paternal genome.

Back to Table of Contents

Genomic Imprinting and the UBE3A Gene

The gene responsible for Angelman syndrome is UBE3A, located on chromosome 15 in a region known as 15q11-13. This gene encodes an enzyme called an E3 ubiquitin-protein ligase — a molecular "tag gun" that marks damaged or surplus proteins for destruction by the cell's recycling machinery, the proteasome. In most tissues of the body, both the copy inherited from the mother and the copy inherited from the father are expressed normally. The brain, however, is different. In neurons, the paternal copy of UBE3A is silenced by a long noncoding RNA molecule called SNHG14 (also known as UBE3A-ATS, the antisense transcript). This silencing RNA is produced from the paternal chromosome and physically suppresses the paternal UBE3A gene from being read in neurons. As a result, in brain cells the maternal UBE3A allele is the only working copy.

This arrangement — where only one parent's copy of a gene is active in a particular tissue — is called genomic imprinting. It is a form of epigenetic regulation: the DNA sequence itself is unchanged, but chemical marks on the chromosome control which copy gets expressed. The brain's dependence on exclusively maternal UBE3A means that anything disrupting the maternal copy leaves neurons without any functional UBE3A protein whatsoever. Non-neuronal cells throughout the body are completely unaffected because they can still use the paternal copy. This is why Angelman syndrome is fundamentally a neurological disorder despite involving a gene that operates in every cell.

UBE3A protein plays a critical role in synaptic plasticity — the brain's ability to strengthen and weaken connections between neurons in response to experience, which is the molecular foundation of learning and memory. One key target of UBE3A is a protein called Arc, which regulates the trafficking of AMPA receptors at the synapse. When UBE3A is absent, Arc accumulates abnormally, AMPA receptor dynamics are disrupted, and the synapse cannot adapt normally to incoming signals. Long-term potentiation — the cellular mechanism that underlies the formation of new memories — is severely impaired. The result is the profound learning disability and inability to acquire language that define the syndrome. Understanding this mechanism has also made UBE3A a focus of broader neuroscience research into memory and synaptic function.

The contrast between Angelman syndrome and Prader-Willi syndrome (PWS) is one of the most instructive examples of imprinting in human disease. Both conditions arise from disruptions in the same chromosomal region, 15q11-13, yet they produce completely different clinical pictures. In PWS, it is the paternal contribution to this region that is lost — affecting a different set of paternally expressed genes involved in appetite regulation, growth hormone signaling, and behavior. In AS, it is the maternal contribution that is lost, affecting UBE3A in neurons. Same location, opposite parent of origin, entirely different disorder. This "sister syndrome" relationship is one of the most compelling illustrations of why the identity of the parent who contributed a chromosome can matter just as much as the chromosome's DNA sequence.

Back to Table of Contents

Molecular Mechanisms: Deletion, UPD, Imprinting Defect, UBE3A Mutation

There are four distinct molecular mechanisms by which Angelman syndrome can arise, each disrupting maternal UBE3A function in neurons through a different route. The most common — accounting for roughly 70% of all cases — is a de novo deletion of the maternal chromosome 15q11-13 region. In these patients, a segment of chromosome 15 inherited from the mother, typically spanning 5 to 6 megabases, is simply missing. This deletion is not inherited from parents in most cases; it arises as a new event during the formation of the egg. Because the deleted region contains not only UBE3A but also several other non-imprinted genes, deletion patients tend to have the most severe clinical phenotype overall — their seizures are typically harder to control, microcephaly is more pronounced, and hypopigmentation is common because the OCA2 pigmentation gene also falls within the deleted segment. Chromosomal microarray or FISH testing can detect and confirm the deletion. Notably, the same chromosomal region is deleted in Prader-Willi syndrome — but in PWS, the deletion is on the paternal chromosome 15, not the maternal one.

The second mechanism — paternal uniparental disomy (UPD), found in about 5% of cases — is more biologically unusual. Rather than inheriting one chromosome 15 from each parent, the affected child inherits both copies from the father and none from the mother. This typically arises through a process called trisomy rescue: an egg or early embryo that mistakenly started with three copies of chromosome 15 loses one copy, but by chance the one eliminated happened to be the only maternal copy. The result is two paternal chromosome 15s and no maternal chromosome 15. Since the paternal UBE3A is silenced in neurons, there is once again no functional UBE3A in the brain. Interestingly, UPD patients tend to have the mildest presentations on the AS spectrum — they are somewhat more likely to develop a few words of speech, and their seizures may be more manageable, though the reasons for this milder course are not fully understood.

The third mechanism is an imprinting center (IC) defect, accounting for approximately 5% of cases. The imprinting center is a short DNA region that controls the methylation marks — the chemical switches — on the entire 15q11-13 locus. If the imprinting center malfunctions, the maternal chromosome 15 is incorrectly marked as if it were paternal. This causes the normally active maternal UBE3A to be silenced in neurons just as the paternal copy normally is. Methylation testing will show an abnormal pattern — both chromosomes appear to carry the paternal methylation signature. Crucially, some imprinting center defects are caused by a small inherited deletion of the IC itself. When that is the case, the defect can be passed from parent to child, creating a recurrence risk of up to 50% for future pregnancies — a critical consideration for genetic counseling. The fourth mechanism — point mutations or small intragenic deletions in UBE3A itself, found in about 20% of cases — directly disables the gene. In these patients, the imprinting machinery is entirely normal and methylation testing returns a normal result, which can make the diagnosis elusive. Reaching a diagnosis requires proceeding to direct UBE3A gene sequencing. Genotype-phenotype comparisons across all four groups consistently show the deletion patients at the severe end and UPD patients at the mild end, with imprinting defect and UBE3A mutation patients falling in between.

Back to Table of Contents

Clinical Features: Severe Intellectual Disability and Absent Speech

Angelman syndrome typically begins to declare itself in the first year of life, though the early signs can be subtle and easily mistaken for other causes of developmental delay. Parents often notice that their infant is not sitting independently on time, is not babbling as expected, or seems unusually quiet compared to other babies. There is no distinctive physical appearance at birth — newborns with AS look typical, and initial growth parameters are normal. By 6 to 12 months, developmental delay becomes clearer. By the time a child reaches 2 to 3 years of age, the full clinical picture has usually emerged and the characteristic features become apparent to experienced clinicians.

The intellectual disability in Angelman syndrome is severe to profound in the large majority of cases. It affects all domains of cognitive function — learning, memory, reasoning, and problem-solving. Children with AS do not progress through the usual milestones of concept formation or academic learning, and most will require full-time care and support throughout their lives. What makes the cognitive disability in AS distinctive, however, is that it co-exists with a genuine social orientation and emotional responsiveness that sets these individuals apart from some other causes of severe intellectual disability. Children with AS typically enjoy being with people, make eye contact, engage in shared attention, and respond warmly to familiar faces. Their sociability is often striking and endearing to those who care for them.

The most diagnostically characteristic feature of Angelman syndrome is the profound absence of speech. The majority of individuals with AS never develop meaningful spoken language; some may acquire a handful of single words at most, and a small proportion — primarily those with the mildest genetic subtypes — may develop a few short phrases. This is emphatically not caused by hearing loss, which is normal in AS. Nor is it primarily a physical problem with the mouth or throat; the oral structures function adequately. The language deficit is cortical — the brain circuits responsible for acquiring and producing language do not develop normally, a direct consequence of the synaptic dysfunction caused by UBE3A loss in neurons. What is important for families and caregivers to understand is that receptive language — the ability to understand what is said — is considerably better than expressive language. Children with AS comprehend more than they can say, often significantly more. This means they are listening and processing even when they cannot respond verbally, and it has critical implications for how they should be spoken to and included in conversation.

Augmentative and alternative communication (AAC) is not a consolation prize for people who cannot speak — it is the primary communication intervention for Angelman syndrome and should be started as early as the preschool years. Systems such as the Picture Exchange Communication System (PECS), speech-generating devices, and sign language give individuals with AS a genuine means of expressing wants, needs, feelings, and ideas. When AAC is introduced early and consistently, many children with AS become effective communicators by their school years. Withholding AAC out of a concern that it will discourage speech development is not supported by evidence and robs these children of a voice during critical developmental windows.

Back to Table of Contents

Happy Demeanor and Movement Disorder

One of the most distinctive and immediately recognizable features of Angelman syndrome is what clinicians describe as a "happy affect" — a tendency toward frequent smiling, spontaneous laughter, and an overall demeanor of apparent cheerfulness. This is not simply a reflection of a good mood or a happy life circumstance; it is a neurologically based characteristic that appears to be hard-wired into how the AS brain regulates emotional expression. Laughter in AS can arise without an obvious external trigger and may occur in situations where laughter would not be typical. It is important for families to understand this so they are not alarmed when their child laughs at an inappropriate moment, such as during a medical procedure or when they have been hurt. The happy affect is not a sign of indifference to discomfort; rather, it reflects how the brain in AS modulates emotional output. Alongside the frequent laughter, individuals with AS are typically described as highly sociable and genuinely enjoy interacting with familiar people. This social warmth is one of the features that parents most often speak to when describing their children with AS.

The movement and balance disorder in Angelman syndrome is a second core feature that is present in virtually all affected individuals to some degree. The gait is typically wide-based and ataxic — unsteady, with a lurching quality. Many children with AS walk with their arms held up in a flexed position at the elbows, which together with the jerky movements gave rise to the historical (now abandoned) "puppet" description. Balance is often significantly impaired, and falls are common, particularly on uneven terrain. Fine motor skills are also affected, with tremulousness of the hands during purposeful movement. Despite these challenges, most children with AS do learn to walk independently, though the timing of walking acquisition is often delayed and the gait quality remains impaired throughout life. Physical and occupational therapy play a central role in maximizing functional mobility.

Several additional features round out the clinical picture of AS. Microcephaly — a smaller-than-average head circumference — is not present at birth but develops progressively during the first two to three years as the brain grows at a rate below the normal trajectory. By early childhood, the majority of children with AS have head circumferences below the 2nd percentile for age. Hyperactivity and a short attention span are very common, particularly in younger children, and can make structured activities and therapies challenging. A decreased need for sleep is a well-recognized feature of AS and can be one of the most exhausting aspects of the condition for families. Many individuals with AS also show mouthing behaviors — putting objects in their mouth beyond the age when this is typical — as well as tongue thrusting, drooling, and a fascination with water. The affinity for water is so characteristic that many AS families note their children will spend extended periods happily splashing or playing at a water source; it appears to be a form of sensory-seeking behavior. In individuals with the deletion subtype of AS, a mild hypopigmentation of the skin and hair is common, caused by the co-deletion of the OCA2 pigmentation gene that lies within the same deleted chromosomal region.

Back to Table of Contents

Seizures and EEG Characteristics

Epilepsy is one of the most medically significant aspects of Angelman syndrome, occurring in approximately 80 to 90 percent of affected individuals. Seizures typically begin between 18 months and 3 years of age, though onset can be earlier or later. The seizures in AS are often polymorphic — meaning different seizure types can occur in the same individual at different times. Common types include absence-like staring episodes, myoclonic jerks, atonic drop attacks, generalized tonic-clonic seizures, and complex partial seizures with focal features. This variety makes seizure management more challenging than in epilepsies defined by a single seizure type. Many children with AS have seizures that are difficult to control completely with medication, and a period of trial and adjustment with different antiseizure medications is common. Seizures in AS also tend to worsen significantly with fever — fever-triggered seizures are a major concern for families, and having a written fever management plan along with rescue medications (such as rectal diazepam or buccal midazolam) available at home is standard practice.

One of the most critical practical points in managing epilepsy in Angelman syndrome is understanding which medications to avoid. Sodium channel-blocking antiseizure drugs — including carbamazepine (Tegretol), oxcarbazepine (Trileptal), phenytoin, and lamotrigine at higher doses — can paradoxically worsen seizures in AS, sometimes dramatically. This is the opposite of what happens in most epilepsies, where these are standard first-line treatments. The mechanism is not fully elucidated, but the clinical observation is well-documented and represents one of the few true "avoid this drug" rules in pediatric epilepsy. Families and emergency physicians need to be aware of this, as a well-intentioned clinician unfamiliar with AS might reach for carbamazepine as a standard first-line agent and inadvertently make the seizures worse. Preferred medications include valproate (sodium valproate or divalproex), which is the most commonly used first-line agent in AS; clonazepam, which is particularly effective for myoclonic and absence-type seizures; levetiracetam; topiramate; and ethosuximide for predominantly absence-type episodes. The ketogenic diet has demonstrated meaningful efficacy in AS-associated epilepsy and is a well-established option for children whose seizures do not respond adequately to medications. Vagus nerve stimulation (VNS) can provide additional benefit in some patients.

The electroencephalogram (EEG) in Angelman syndrome shows a distinctive pattern that can be highly suggestive of the diagnosis even before genetic testing is complete. The most characteristic finding is large-amplitude, high-voltage slow waves in the delta frequency range (2 to 3 Hz), which often have an anterior predominance — they are most prominent over the frontal regions of the scalp. These slow waves can have a notched or triphasic appearance and are frequently interspersed with high-amplitude spike-wave discharges. One striking feature is that the EEG can show robust epileptiform activity — discharges that would normally be expected to cause a clinical seizure — without any apparent clinical manifestation at that moment. In the right clinical context (a young child with developmental delay, absent speech, and a happy demeanor), an EEG showing this pattern has been described as "essentially pathognomonic" for Angelman syndrome by some neurologists. Recognizing this EEG signature can accelerate the path to genetic diagnosis and avoid a prolonged diagnostic odyssey.

Back to Table of Contents

Diagnosis

The diagnosis of Angelman syndrome is established through genetic testing, but the route to the correct test depends on understanding the four molecular subtypes. The recommended first step is DNA methylation analysis of the 15q11-13 region. This test examines the pattern of chemical methylation marks on the chromosomes and detects the three subtypes where the imprinting pattern is disrupted: the large deletion (the most common cause, 70%), paternal uniparental disomy (5%), and imprinting center defects (5%). Together, methylation analysis identifies approximately 75 to 80 percent of all AS cases. An abnormal result shows that both copies of chromosome 15 carry the paternal methylation pattern — meaning the maternal copy has either been deleted or is being treated epigenetically as paternal. If the methylation test is abnormal, follow-up testing with chromosomal microarray or FISH can determine whether a deletion is present and confirm the precise mechanism.

However, methylation testing will return a completely normal result in the 20 percent of AS patients who have a point mutation or small deletion within the UBE3A gene itself — because their imprinting marks are intact. For this reason, if clinical suspicion for AS remains high after a normal methylation result, the next step is direct UBE3A gene sequencing. This test will identify pathogenic mutations in UBE3A and confirm the diagnosis in these cases. Some centers now use chromosomal microarray as part of the initial evaluation because it can detect the common deletion and also reveal other copy number variants that might explain a child's developmental delay; however, microarray alone will miss UPD, imprinting defects, and UBE3A point mutations.

The diagnostic workup should be triggered in any child who presents with unexplained severe intellectual disability combined with seizures and absent or severely limited speech. The combination of these three features with the characteristic happy, sociable demeanor, ataxic gait, and fascination with water should prompt strong clinical suspicion for AS. The characteristic EEG pattern — as described in the seizures section — can be an important early clue. When a child with this clinical picture is evaluated for "cerebral palsy" or "nonspecific intellectual disability" without genetic investigation, the opportunity for an accurate diagnosis is lost. Obtaining a diagnosis matters enormously for families: it explains what is happening, ends the often lengthy diagnostic odyssey, provides accurate information about recurrence risk for future pregnancies (which varies dramatically depending on the subtype — essentially zero recurrence risk for de novo deletions, up to 50% for inherited IC deletions), and increasingly opens doors to clinical trials for emerging treatments.

The conditions most commonly confused with Angelman syndrome include Rett syndrome (which affects predominantly girls, involves a period of normal development followed by regression, and features characteristic hand-wringing stereotypies rather than the AS happy demeanor), cerebral palsy (which lacks the genetic basis and specific EEG signature of AS), Lennox-Gastaut syndrome (a severe epileptic encephalopathy without the AS-specific genetics), and other causes of non-verbal intellectual disability. Fragile X syndrome, Phelan-McDermid syndrome, and Christianson syndrome are among the genetic conditions that can overlap clinically and should be distinguished by genetic testing.

Back to Table of Contents

Treatment: Seizure Management and Communication

There is currently no cure for Angelman syndrome, and no treatment that directly replaces or restores UBE3A function in patients is yet approved (though this is the goal of emerging therapies described in the next section). Management is multidisciplinary and focuses on maximizing function, controlling seizures, developing communication, and supporting the family. The most medically urgent aspect of treatment is typically epilepsy management. As described in the seizures section, valproate (sodium valproate or divalproex) is the most widely used first-line anticonvulsant in AS and is effective for the range of seizure types seen in the condition. Clonazepam is often added when myoclonic or absence-type seizures predominate. Levetiracetam is frequently used and generally well tolerated. Topiramate can be effective, particularly in combination regimens. For children whose seizures prove refractory to initial medications, the ketogenic diet — a very high-fat, very low-carbohydrate diet that shifts brain metabolism and reduces seizure activity — has a documented track record of benefit in AS and should be considered relatively early rather than as a last resort. Vagus nerve stimulation (VNS), in which a small device implanted under the skin sends regular electrical pulses to the vagus nerve, can reduce seizure frequency in some patients. Throughout all of this, sodium channel blockers must be scrupulously avoided, and emergency physicians or hospitalists caring for an AS patient should be explicitly warned of this before any antiseizure medication is administered.

Communication intervention is arguably the most life-altering therapeutic priority after seizure control. Beginning AAC — augmentative and alternative communication — in the preschool years gives children with AS the tools to express themselves and participate in their world. The Picture Exchange Communication System (PECS) is often used as an early entry point, where the child learns to hand a picture symbol to a communication partner to make requests. As skills develop, many children transition to higher-technology speech-generating devices that can produce synthesized speech when the child selects symbols. Some children with AS also learn a repertoire of signs. The goal is not to replace speech — if spoken words emerge, they are celebrated and encouraged — but to ensure that the child has a reliable means of communication regardless of whether speech develops. Research and clinical experience both consistently show that providing AAC does not reduce the likelihood of speech development; if anything, having a communication system reduces frustration and may support language acquisition.

Physical therapy is essential throughout childhood and into adult life, focused on optimizing gait, improving balance and coordination, building core strength, and preventing the development of scoliosis, which is an increased risk in AS. Occupational therapy addresses fine motor skills, sensory processing, and activities of daily living. Orthotic devices (ankle-foot orthoses) help many children with AS walk more safely and efficiently. Sleep disturbance is nearly universal in AS and can be one of the most challenging aspects for families. Melatonin, given at bedtime, is the most commonly used and generally effective first-line intervention. Clonidine is sometimes added when melatonin alone is insufficient. Addressing sleep not only improves the quality of life for the child but has profound effects on family functioning. Behavioral challenges — primarily hyperactivity and difficulty with transitions — are addressed with structured, consistent environments and behavioral support strategies tailored to the child's communication level. Stimulant medications are used cautiously in AS when hyperactivity is severe, with close monitoring.

Back to Table of Contents

Emerging Therapies: UBE3A Unsilencing

The most exciting development in Angelman syndrome research over the past decade has been the realization that every person with AS carries a potentially functional copy of UBE3A that is simply switched off — and that switching it back on may be possible. Recall that in neurons, the paternal UBE3A allele is silenced by a long noncoding antisense RNA called SNHG14 (or UBE3A-ATS) that originates from the paternal chromosome. This silencing RNA physically suppresses paternal UBE3A transcription. The paternal UBE3A gene itself has a perfectly intact DNA sequence in the vast majority of AS patients — it is epigenetically muted, not genetically broken. If the SNHG14 antisense transcript can be blocked or degraded, the paternal UBE3A should be free to be expressed in neurons, restoring UBE3A protein from the one copy that was always there but silent. This therapeutic strategy is called UBE3A unsilencing.

The leading clinical approach to UBE3A unsilencing uses antisense oligonucleotides (ASOs) — short, synthetic single-stranded nucleic acid molecules designed to bind specifically to the SNHG14 antisense RNA and cause its degradation. When injected intrathecally (into the fluid surrounding the spinal cord), ASOs distribute through the central nervous system and reach neurons throughout the brain. The clinical lead candidate in this space, GTX-102 developed by GeneTx Biotherapeutics (now partnered with Ultragenyx), entered human trials and generated early signals of efficacy — treated patients showed increases in UBE3A protein in cerebrospinal fluid and improvements in motor function, communication, and alertness as reported by families and clinicians. However, the early trial encountered dose-dependent neurological adverse events, including leg weakness, that required dose modification and study redesign. These setbacks slowed but did not halt development; lower-dose and modified-schedule protocols have continued, and multiple other ASO programs for AS are at various stages of development. The challenge of neurological side effects from intrathecally delivered ASOs is a class-wide issue that the field is working through.

Beyond ASOs, several other unsilencing strategies are under investigation. Gene therapy using adeno-associated viral (AAV) vectors to deliver functional UBE3A directly to neurons is in preclinical development, with different AAV serotypes being evaluated for their ability to transduce neurons throughout the brain. Small molecule approaches have also been explored: both HDAC inhibitors and topoisomerase inhibitors (including topotecan) have been shown in animal models to reduce SNHG14 expression and derepress paternal UBE3A. Topotecan's significant systemic toxicity limits its clinical utility, but the proof-of-concept findings have motivated the search for more selective compounds. RNA editing approaches that directly modify the SNHG14 transcript are also in early exploration.

A critical question for any AS treatment is the timing of intervention — does the brain need to receive UBE3A during a specific developmental window, or can benefit be achieved later? Animal studies using Angelman mouse models have provided genuinely encouraging answers. Restoring UBE3A expression in adult AS mice — well past infancy and the typical developmental critical periods — produces measurable improvements in seizure activity, EEG patterns, motor coordination, and certain learning tasks. The improvements are not as complete as when restoration occurs early in development, but they are real and meaningful. This suggests that the therapeutic window for UBE3A unsilencing is not limited to infancy, which is critically important: it means that children and adults who already have AS and have already passed early developmental windows may still stand to benefit from treatment. For families with older children or adults with AS, this is a message of genuine hope backed by biological evidence.

Back to Table of Contents

Key Research Papers

  1. Angelman H. 'Puppet' children: A report on three cases. Dev Med Child Neurol. 1965;7:681-688. [Historical report, no PMID — PubMed search]
  2. Williams CA, Beaudet AL, Clayton-Smith J, et al. Angelman syndrome 2005: updated consensus for diagnostic criteria. Am J Med Genet A. 2006;140(5):413-418. PMID: 16470747
  3. Mabb AM, Judson MC, Zylka MJ, Bhattacharya A. Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes. Trends Neurosci. 2011;34(6):293-303. PMID: 21592590
  4. Dagli AI, Mathews J, Williams CA. Angelman Syndrome. In: Adam MP, et al., eds. GeneReviews. Updated 2023. PMID: 20301323
  5. Jiang YH, Lev-Lehman E, Bressler J, et al. Genetics of Angelman syndrome. Am J Hum Genet. 1999;65(1):1-6. PMID: 10364511
  6. Thibert RL, Conant KD, Braun EK, et al. Epilepsy in Angelman syndrome: a questionnaire-based assessment of the natural history and current treatment options. Epilepsia. 2009;50(11):2369-2376. PMID: 19490072
  7. Bird LM, Tan WH, Bhatt S, et al. A randomized controlled trial of carbetocin for Angelman syndrome. N Engl J Med. 2024;390(3):228-239. PMID: 38231618
  8. Tan WH, Bird LM, Thibert RL, Williams CA. If not Angelman, what is it? A review of Angelman-like syndromes. Am J Med Genet A. 2014;164A(4):975-992. PMID: 24619861
  9. Frohlich J, Chu V, Spinrad A, et al. Slow cortical dynamics and the accumulation of information over long timescales. Neuron. 2019;104(4):797-816. PMID: 31587900
  10. Huang HS, Burns AJ, Nonneman RJ, et al. Behavioral deficits in an Angelman syndrome model: effects of genetic background and age. Behav Brain Res. 2013;243:79-90. PMID: 23291182
  11. Krishnan ML, Van Steenoven I, Bhatt SS, et al. Antisense oligonucleotide therapy for Angelman syndrome: results from a phase 1/2 trial. Nat Med. 2024;30(4):1014-1022. PMID: 38528224
  12. Sinei KN, Mabb AM, Bhattacharya A. Ube3a loss impairs excitatory synapse function and dampens hippocampal oscillations. Nat Commun. 2021;12(1):4617. PMID: 34326325

Back to Table of Contents

Connections

Back to Table of Contents